Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 mutation
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 mutation
Cholangiocarcinoma
HER-2 mutation
Cholangiocarcinoma
neratinib
Sensitive: C3 – Early Trials
Nat Commun - 3 days (New C3)
neratinib
Sensitive
:
C3
Nat Commun - 3d
neratinib
Sensitive: C3 – Early Trials
Nat Commun - 3 days
neratinib
Sensitive
:
C3
Nat Commun - 3 days - (New C3)
HER-2 mutation
Gallbladder Cancer
HER-2 mutation
Gallbladder Cancer
neratinib
Sensitive: C3 – Early Trials
Nat Commun - 3 days (New C3)
neratinib
Sensitive
:
C3
Nat Commun - 3d
neratinib
Sensitive: C3 – Early Trials
Nat Commun - 3 days
neratinib
Sensitive
:
C3
Nat Commun - 3 days - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
BI 1810631
Sensitive: C2 – Inclusion Criteria
IASLC-TTLC 2023 - 1 week (New C3)
BI 1810631
Sensitive
:
C2
IASLC-TTLC 2023 - 1wk
BI 1810631
Sensitive: C2 – Inclusion Criteria
IASLC-TTLC 2023 - 1 week
BI 1810631
Sensitive
:
C2
IASLC-TTLC 2023 - 1 week - (New C3)
HER-2 mutation
Biliary Tract Cancer
HER-2 mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 3wk
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
trastuzumab + pertuzumab
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
fam-trastuzumab deruxtecan-nxki
Sensitive: A1 - Approval
fam-trastuzumab deruxtecan-nxki
Sensitive
:
A1
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
afatinib
Resistant: A2 - Guideline
afatinib
Resistant
:
A2
afatinib
Resistant: A2 - Guideline
afatinib
Resistant
:
A2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab
Resistant: A2 - Guideline
trastuzumab
Resistant
:
A2
trastuzumab
Resistant: A2 - Guideline
trastuzumab
Resistant
:
A2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
ado-trastuzumab emtansine
Sensitive: A2 - Guideline
ado-trastuzumab emtansine
Sensitive
:
A2
ado-trastuzumab emtansine
Sensitive: A2 - Guideline
ado-trastuzumab emtansine
Sensitive
:
A2
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
BDTX-189
Sensitive: B - Late Trials
BDTX-189
Sensitive
:
B
BDTX-189
Sensitive: B - Late Trials
BDTX-189
Sensitive
:
B
HER-2 mutation
Breast Cancer
HER-2 mutation
Breast Cancer
ribociclib
Sensitive: B - Late Trials
ribociclib
Sensitive
:
B
ribociclib
Sensitive: B - Late Trials
ribociclib
Sensitive
:
B
HER-2 mutation
Colorectal Cancer
HER-2 mutation
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Breast Cancer
HER-2 mutation
Breast Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
fam-trastuzumab deruxtecan-nxki
Sensitive: C1 - Off-label
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C1
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
HER-2 mutation
Hormone Receptor Positive Breast Cancer
HER-2 mutation
Hormone Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
trastuzumab + neratinib
Sensitive
:
C2
trastuzumab + neratinib
Sensitive: C2 – Inclusion Criteria
trastuzumab + neratinib
Sensitive
:
C2
HER-2 mutation
Gastric Cancer
HER-2 mutation
Gastric Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Lung Cancer
HER-2 mutation
Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Urothelial Cancer
HER-2 mutation
Urothelial Cancer
afatinib
Sensitive: C2 – Inclusion Criteria
afatinib
Sensitive
:
C2
afatinib
Sensitive: C2 – Inclusion Criteria
afatinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
tarloxotinib bromide
Sensitive: C2 – Inclusion Criteria
tarloxotinib bromide
Sensitive
:
C2
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Cervical Cancer
HER-2 mutation
Cervical Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
pyrotinib
Sensitive: C2 – Inclusion Criteria
pyrotinib
Sensitive
:
C2
HER-2 mutation
Gastroesophageal Junction Adenocarcinoma
HER-2 mutation
Gastroesophageal Junction Adenocarcinoma
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
pembrolizumab + margetuximab
Sensitive
:
C2
pembrolizumab + margetuximab
Sensitive: C2 – Inclusion Criteria
pembrolizumab + margetuximab
Sensitive
:
C2
HER-2 mutation
Breast Cancer
HER-2 mutation
Breast Cancer
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
neratinib
Sensitive: C2 – Inclusion Criteria
neratinib
Sensitive
:
C2
HER-2 mutation
Lung Cancer
HER-2 mutation
Lung Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
trastuzumab + neratinib
Sensitive: C3 – Early Trials
trastuzumab + neratinib
Sensitive
:
C3
trastuzumab + neratinib
Sensitive: C3 – Early Trials
trastuzumab + neratinib
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
neratinib + temsirolimus
Sensitive: C3 – Early Trials
neratinib + temsirolimus
Sensitive
:
C3
neratinib + temsirolimus
Sensitive: C3 – Early Trials
neratinib + temsirolimus
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
U3-1402
Sensitive: C3 – Early Trials
U3-1402
Sensitive
:
C3
HER-2 mutation
Biliary Tract Cancer
HER-2 mutation
Biliary Tract Cancer
neratinib
Sensitive: C3 – Early Trials
neratinib
Sensitive
:
C3
neratinib
Sensitive: C3 – Early Trials
neratinib
Sensitive
:
C3
HER-2 mutation
Lung Adenocarcinoma
HER-2 mutation
Lung Adenocarcinoma
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
trastuzumab + pertuzumab
Sensitive
:
C3
trastuzumab + pertuzumab
Sensitive: C3 – Early Trials
trastuzumab + pertuzumab
Sensitive
:
C3
HER-2 mutation
Squamous Cell Carcinoma of Head and Neck
HER-2 mutation
Squamous Cell Carcinoma of Head and Neck
cetuximab + ISU104
Sensitive: C3 – Early Trials
cetuximab + ISU104
Sensitive
:
C3
cetuximab + ISU104
Sensitive: C3 – Early Trials
cetuximab + ISU104
Sensitive
:
C3
HER-2 mutation
Thymic Carcinoma
HER-2 mutation
Thymic Carcinoma
pyrotinib
Sensitive: C3 – Early Trials
pyrotinib
Sensitive
:
C3
pyrotinib
Sensitive: C3 – Early Trials
pyrotinib
Sensitive
:
C3
HER-2 mutation
Solid Tumor
HER-2 mutation
Solid Tumor
KN046 + KN026
Sensitive: C3 – Early Trials
KN046 + KN026
Sensitive
:
C3
KN046 + KN026
Sensitive: C3 – Early Trials
KN046 + KN026
Sensitive
:
C3
HER-2 mutation
Colorectal Cancer
HER-2 mutation
Colorectal Cancer
pyrotinib
Sensitive: C3 – Early Trials
pyrotinib
Sensitive
:
C3
pyrotinib
Sensitive: C3 – Early Trials
pyrotinib
Sensitive
:
C3
HER-2 mutation
Non Small Cell Lung Cancer
HER-2 mutation
Non Small Cell Lung Cancer
PD-L1 inhibitor
Resistant: C3 – Early Trials
PD-L1 inhibitor
Resistant
:
C3
PD-L1 inhibitor
Resistant: C3 – Early Trials
PD-L1 inhibitor
Resistant
:
C3
HER-2 mutation
Lung Adenocarcinoma
HER-2 mutation
Lung Adenocarcinoma
afatinib
Sensitive: C3 – Early Trials
afatinib
Sensitive
:
C3
afatinib
Sensitive: C3 – Early Trials
afatinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login